by John A. Jenkins | Nov 26, 2024 | Corporate Investigators, FOIA, Hedge Funds, Law Firms, Litigation, News Media, Politics, SEC
FOIAengine: Requests Signaled Trouble for Guatam Adani Guatam Adani, India’s most powerful tycoon and a close ally of Prime Minister Narendra Modi, knows what it’s like to stare death in the face and survive. Danger has a knack for finding him. But each time – a...
by Randy E. Miller | Nov 20, 2024 | FOIA, FTC, News Media
FOIAengine: News Media Seeks Records from Consumer Sentinel Network New research from PoliScio Analytics demonstrates how journalists use Freedom of Information Act requests to the Federal Trade Commission to uncover bad news about companies and individuals. The FTC...
by Randy E. Miller | Aug 21, 2024 | Antitrust, Cryptocurrency, FOIA, FTC, News Media
FOIAengine Analysis Reveals Targets and Topics News media outlets continued to be the leading submitters of Freedom of Information Act requests to the Federal Trade Commission during the first half of 2024, with many of the requests focused on the agency’s...
by John A. Jenkins | Aug 14, 2024 | FOIA, Litigation, News Media, SEC, Short-Selling
FOIAengine: How the “Bounty Hunter of Wall Street” Hedged His Bets As a young man, Andrew Left was a “real serious kid” – and very religious. He wanted to be a rabbi. But then, in his telling, Left saw a newspaper ad that said, “Earn $100,000.” “I thought, ‘Yeah,...
by John A. Jenkins | Jun 13, 2024 | EPA, FOIA, Law Firms, Litigation, News Media
FOIAengine: ProPublica Reporter Made Dozens of FOIA Requests to EPA Before Dropping a Bombshell Minnesota-based 3M styles itself as a friendly, people-first company in the heartland of America, innovating through curiosity. Its 93,000 employees make all sorts of...
by Randy E. Miller | May 30, 2024 | FDA, FOIA, Hedge Funds, News Media, Pharmaceuticals, Stock Market
FOIAengine: Requests Show FDA Still Under Pressure This week, we’re taking a closer look at the numerous Freedom of Information Act requests recently filed with the Food and Drug Administration concerning the problematic India pharmaceutical industry. As we noted in...
